Post by Deleted on Oct 17, 2017 22:27:21 GMT
I was looking at some people going back and forth on yahoo concerning ARRY. One of the posters stated that the reason it has pulled back lately is BMY's, opdivo. They stated it has been granted fast track for the area of melanoma, that Arry's main stage 3 drug is competing. I looked it up and yes it has been granted fast track. However, I'm clueless on the impacts to Arry. I've noticed with OPKO, we think we have competition than a more astute poster will find dd that it doesn't even compete. Anyone with any insight?